Targeting the toll-like receptor/interleukin 1 receptor pathway in human diseases: Rational design of MYd88 inhibitors

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 222-226

  Loiarro, Maria ^a,b   Ruggiero, Vito ^c   Sette, Claudio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Prassis Sigma Tau Research Institute   (Italy)

Author keywords

Human diseases; MyD88; Signaling; Targeting; Toll like receptor interleukin 1 receptor

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; MUTANT PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDOMIMETIC AGENT; PROTEIN INHIBITOR; ST 2825; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CARTILAGE CELL; CELL PROLIFERATION; CONFERENCE PAPER; DIMERIZATION; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LYMPHOMA; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WALDENSTROEM MACROGLOBULINEMIA;

DRUG DESIGN; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LYMPHOMA; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDES; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; TOLL-LIKE RECEPTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84877619379     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.02.003     Document Type: Conference Paper

References (25)

1. T. Kawai, S. Akira Toll-like receptors and their crosstalk with other innate receptors in infection and immunity Immunity 34 2011 637 650
2. D. Tang, R. Kang, C.B. Coyne PAMPs and DAMPs: signal 0s that spur autophagy and immunity Immunol Rev 249 2012 158 175
3. Y. Xu, X. Tao, B. Shen Structural basis for signal transduction by the toll/interleukin-1 receptor domains Nature 408 2000 111 115
4. L.A. O'Neill, A.G. Bowie The family of five: TIR-domain-containing adaptors in toll-like receptor signaling Nat Rev Immunol 7 2007 353 364 (Pubitemid 46674493)
5. G. Hardiman, F.L. Rock, S. Balasubramanian Molecular characterization and modular analysis of human MyD88 Oncogene 13 1996 2467 2475 (Pubitemid 27026031)
6. S.C. Lin, Y.C. Lo, H. Wu Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signaling Nature 465 2010 885 890
7. J. Brown, H. Wang, G.N. Hajishengallis TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk J Dent Res 90 2011 417 427
8. S.K. Drexler, B.M. Foxwell The role of toll-like receptors in chronic inflammation Int J Biochem Cell Biol 42 2010 506 518
9. M.A. Merrell, J.M. Ilvesaro, N. Lehtonen Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity Mol Cancer Res 4 2006 437 447 (Pubitemid 44197039)
10. M. Fukata, A. Chen, A.S. Vamadevan Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors Gastroenterology 133 2007 1869 1881
11. S. Rakoff-Nahoum, R. Medzhitov Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88 Science 317 2007 124 127 (Pubitemid 47056471)
12. J.B. Swann, M.D. Vesely, A. Silva Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis Proc Natl Acad Sci U S A 105 2008 652 656 (Pubitemid 351171763)
13. V.N. Ngo, R.M. Young, R. Schmitz Oncogenically active MYD88 mutations in human lymphoma Nature 470 2011 115 119
14. S.P. Treon, L. Xu, G. Yang MYD88 L265P somatic mutation in Waldenström's macroglobulinemia N Engl J Med 367 2012 826 833
15. X.S. Puente, M. Pinyol, V. Quesada Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia Nature 475 2011 101 115
16. M. Loiarro, V. Ruggiero, C. Sette Targeting TLR/IL-1R signaling in human diseases Mediators Inflamm 2010 2010 674363
17. D.J. Connolly, L.A. O'Neill New developments in toll-like receptor targeted therapeutics Curr Opin Pharmacol 12 2012 510 518
18. M. Loiarro, G. Gallo, N. Fantò Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases J Biol Chem 284 2009 28093 28103
19. H. von Bernuth, C. Picard, Z. Jin Pyogenic bacterial infections in humans with MyD88 deficiency Science 321 2008 691 696
20. M. Loiarro, C. Sette, G. Gallo Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-(kappa)-B J Biol Chem 280 2005 15809 15814 (Pubitemid 40616701)
21. C. Li, J. Zienkiewicz, J. Hawiger Interactive sites in the MyD88 toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway J Biol Chem 280 2005 26152 26159 (Pubitemid 41022210)
22. Carminati P, Gallo G, Ruggiero V, et al. MyD88 homodimerization inhibitors. Patent Number WO2006067091.
23. M. Loiarro, F. Capolunghi, N. Fantò Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound J Leukoc Biol 82 2007 801 810 (Pubitemid 47511039)
24. R. Ahmad, J. Sylvester, M. Zafarullah MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation Cell Signal 19 2007 2549 2557 (Pubitemid 47531934)
25. F. Capolunghi, M.M. Rosado, S. Cascioli Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients Rheumatology (Oxford) 49 2010 228119